BioPharmSignal logoBioPharmSignal

Company Profile

Emergent BioSolutions Stock Price, News & Catalysts

Ticker:
EBS
Exchange:
NYSE
Sector:
Biopharma
Location:
United States

Stock performance

4.55 USD (+2.25%)

Close

Last updated: August 12, 2026

424M USD

Market cap

Why the stock is moving

As of Aug 12, 2026, EBS closed up 2.25% at $4.55. No new same-company headline was identified in the current news window.

Company overview

Business overview

Emergent BioSolutions is a biodefense and specialty products company focused on public-health preparedness, vaccines, and medical countermeasures. Its business is centered on government and specialty healthcare contracts.

Geographic Base and Sector Classification

Headquartered in the United States and listed on NYSE, Emergent sits in specialty healthcare and biodefense.

Business Model Characteristics

The company depends on government contracts, product supply, and the execution of its public-health franchise.

Position Within the Biotechnology Landscape

Emergent is outside biotech proper and belongs to the biodefense and specialty-products layer.

Future catalysts

  • Emergent BioSolutions’ catalysts are biodefense contract awards, manufacturing execution, and any update on its public-health products. The market will care about whether the company can keep its federal-defense and infectious-disease franchise stable.

Recent news

  1. 01

    Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

  2. 02

    Emergent BioSolutions to Participate in Upcoming Investor Conferences

  3. 03

    Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

  4. 04

    Emergent BioSolutions Reports First Quarter 2026 Financial Results

  5. 05

    Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

SIGA

SIGA

PRPH

ProPhase Labs

SMTI

Sanara MedTech

BHC

Bausch Health

ACHV

Achieve Life Sciences

INDV

Indivior

DERM

Journey Medical Corporation

TXMD

TherapeuticsMD

Frequently Asked Questions

What is the current stock price of Emergent BioSolutions (EBS)?

Emergent BioSolutions (EBS) most recently closed at 4.55 USD, a +2.25% move versus the previous session.

What is the market cap of Emergent BioSolutions (EBS)?

Emergent BioSolutions currently has a market capitalization of 424M USD on BioPharmSignal.

What does Emergent BioSolutions do?

Emergent BioSolutions is a biodefense and specialty products company focused on public-health preparedness, vaccines, and medical countermeasures. Its business is centered on government and specialty healthcare contracts.

On which exchange is EBS stock listed?

Emergent BioSolutions (EBS) is associated with NYSE, United States, Biopharma.

What is Emergent?

Emergent BioSolutions’ catalysts are biodefense contract awards, manufacturing execution, and any update on its public-health products.

Which conditions is Emergent BioSolutions targeting with Emergent?

Emergent BioSolutions’ catalysts are biodefense contract awards, manufacturing execution, and any update on its public-health products.

How does Emergent BioSolutions describe recent progress with Emergent?

Emergent BioSolutions’ catalysts are biodefense contract awards, manufacturing execution, and any update on its public-health products.

What is BioSolutions?

Emergent BioSolutions is a biodefense and specialty products company focused on public-health preparedness, vaccines, and medical countermeasures.